07 January 2026
07 January 2026
Nimbus will apply its computational chemistry and structure-based drug design to a discovery programme in obesity treatment.
The US health agency now recommends 11 vaccines for routine administration in childhood, which it says better allows for “flexibility and choice”.
According to Citi analysts, Amgen’s acquisition of Dark Blue could further drive the strength of Amgen’s early oncology pipeline.
CK0804 is an allogeneic, off‑the‑shelf Treg cell therapy.
Zai Lab holds exclusive rights to develop and commercialise Augtyro in mainland China.
The NDA follows positive results from the Phase III global placebo-controlled, randomised VERIFY trial.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
